A novel BRD4 inhibitor suppresses osteoclastogenesis and ovariectomized osteoporosis by blocking RANKL-mediated MAPK and NF-κB pathways

Documenti analoghi

• Tyloxapol inhibits RANKL-stimulated osteoclastogenesis and ovariectomized-induced bone loss by restraining NF-κB and MAPK activation
  di: Guo, Wen, et al.
  Pubblicazione: (2021)
• Sesamolin Protects Mice From Ovariectomized Bone Loss by Inhibiting Osteoclastogenesis and RANKL-Mediated NF-κB and MAPK Signaling Pathways
  di: Yang, Xue, et al.
  Pubblicazione: (2021)
• Niloticin inhibits osteoclastogenesis by blocking RANKL–RANK interaction and suppressing the AKT, MAPK, and NF-κB signaling pathways
  di: Huanhuan Xu, et al.
  Pubblicazione: (2022-05-01)
• Calycosin Suppresses RANKL-Mediated Osteoclastogenesis through Inhibition of MAPKs and NF-κB
  di: Quan, Gui-Hua, et al.
  Pubblicazione: (2015)
• Galangin suppresses RANKL‐induced osteoclastogenesis via inhibiting MAPK and NF‐κB signalling pathways
  di: Li, Xiucheng, et al.
  Pubblicazione: (2021)